SMARCA4 and rhabdoid tumor: Carriers of heterozygous constitutional mutations of SMARCB1 or SMARCA4 are prone to develop rhabdoid tumors (RT), which have been clinically named as rhabdoid tumor predisposition syndromes 1 (RTS1) and 2 (RTS2), respectively [144, 145].